Señales en vivo de TRVN | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 may 2024 @ 16:00):

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders...

Stats
Volumen de hoy	115 764
Volumen promedio	208 331
Capitalización de mercado	6.68M
EPS	$0 ( 2024-04-04 )
Próxima fecha de ganancias	( $-0.470 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0700
ATR14	$0.00800 (1.79%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Drake Patricia M.	Buy	25 000	Common Stock
2023-12-14	Drake Patricia M.	Sell	1 835	Common Stock
2023-12-14	Drake Patricia M.	Buy	50 000	Common Stock
2023-12-14	Bourdow Carrie L.	Buy	100 000	Common Stock
2023-12-14	Bourdow Carrie L.	Sell	7 123	Common Stock

INSIDER POWER
92.77
Last 98 transactions
Buy: 7 332 092 \| Sell: 537 308

Volumen Correlación

Largo: -0.17 (neutral)

Corto: 0.41 (neutral)

Signal:(64.223) Neutral

Trevena Inc Correlación

10 Correlaciones Más Positivas
HCDIP	0.954
RMGC	0.953
PRTS	0.947
BIRD	0.947
FLGT	0.946
DCFC	0.945
INFI	0.945
QLGN	0.938
ADTN	0.938
ACAD	0.938

10 Correlaciones Más Negativas
GHRS	-0.965
STAY	-0.95
ACAB	-0.943
GLLI	-0.942
GGAL	-0.938
KINS	-0.938
CIIG	-0.936
RAM	-0.935
THRN	-0.935
RAIN	-0.933

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Trevena Inc Correlación - Moneda/Commodity

0.10
( neutral )

0.11
( neutral )

0.00
( neutral )

Trevena Inc Finanzas

Annual	2022
Ingresos:	$-418 000
Beneficio Bruto:	$-3.44M (822.01 %)
EPS:	$-7.59

FY	2022
Ingresos:	$-418 000
Beneficio Bruto:	$-3.44M (822.01 %)
EPS:	$-7.59

FY	2021
Ingresos:	$567.00
Beneficio Bruto:	$-387.00 (-68.25 %)
EPS:	$-0.0101

FY	2020
Ingresos:	$3.07M
Beneficio Bruto:	$2.89M (94.07 %)
EPS:	$-5.75

Financial Reports:

No articles found.

Trevena Inc

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.